The Potential Benefit of Three vs. Six Cycles of Carboplatin, Etoposide, and Vincristine in Postenucleation High-Risk Patients with IRSS Stage I Retinoblastoma-Reference-Cited by-同舟云学术

The Potential Benefit of Three vs. Six Cycles of Carboplatin, Etoposide, and Vincristine in Postenucleation High-Risk Patients with IRSS Stage I Retinoblastoma

Published:2016-05-09 Issue:11 Volume:41 Page:1507-1512
ISSN:0271-3683
Container-title:Current Eye Research
language:en
Short-container-title:Current Eye Research

Author:

Ye Huijing¹,Du Yi²,Chen Rongxin¹,Luo Xin³,Mao Yuxiang¹,Ai Siming¹,Ma Wenfang¹,Ding Yungang¹,Li Qian¹,Yang Huasheng¹

Affiliation:

1. State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China

2. Department of Ophthalmology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China

3. Affiliated Hospital of Zunyi Medical College, Zunyi, Guizhou, China

Funder

Sun Yat-Sen University Clinical Research 5010 Program

Funding from Traditional Chinese Medicine Bureau of Guangdong Province, China

Science and Technology Program of Guangdong Province, China

Science and Technology Program of Guangzhou, China

Publisher

Informa UK Limited

Subject

Cellular and Molecular Neuroscience,Sensory Systems,Ophthalmology

Link

https://www.tandfonline.com/doi/pdf/10.3109/02713683.2015.1130230

Reference33 articles.

1. The pediatric retina could be the clue to systemic disease

2. The prognosis of retinoblastoma in terms of survival. A computer assisted study. Part II

3. Postenucleation Adjuvant Therapy in High-Risk Retinoblastoma

4. Adjuvant Chemotherapy With Vincristine, Doxorubicin, and Cyclophosphamide in the Treatment of Postenucleation High Risk Retinoblastoma

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Management of Intraocular Retinoblastoma: ICMR Consensus Guidelines;Indian Journal of Pediatrics;2024-04-13

2. Treatment adherence in retinoblastoma: A retro‐prospective cohort study in Ivory Coast and the Democratic Republic of Congo;Cancer Reports;2023-12-26